Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00430092 · ClinicalTrials.gov registry record · Phase 3
Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)
A Phase 3 study, sponsored by Sirion Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 219
- Enrollment target
NCT00430092: Completed Phase 3 study, sponsored by Sirion Therapeutics.
NCT00430092 is a Phase 3 study that has completed, run by Sirion Therapeutics. The registered enrollment target is 219 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00430092, a Phase 3 study, has completed, sponsored by Sirion Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 219 participants
- Enrollment target
Study Summary
The purpose of this phase III study is to determine the efficacy of difluprednate in the treatment of inflammation following ocular surgery.
Primary Outcome
Measured on a 0 to 4 scale: "0" is ≤ 1 cell; "1" is 2-10 cells; "2" is 11-20 cells; "3" is 21-50 cells; "4" is \> 50 cells.
Interventions
- DRUG Placebo
- DRUG Difluprednate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Phase | Phase 3 |
What the finished NCT00430092 record still lists
NCT00430092 is an interventional study that assigns participants to a tested intervention. The registered 219 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00430092 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00430092 about?
NCT00430092 is a clinical study titled "Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)". The purpose of this phase III study is to determine the efficacy of difluprednate in the treatment of inflammation following ocular surgery.
What is the current status of trial NCT00430092?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 219 participants.
What interventions are being tested in trial NCT00430092?
The interventions under investigation include: Placebo (DRUG), Difluprednate (DRUG).
Who is sponsoring clinical trial NCT00430092?
This trial is sponsored by Sirion Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00430092's enrollment target sits among peer trials
219 1329th of 2000 higher than 670 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05196035 · 219 participants · Phase 3
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
- NCT05608434 · 219 participants · Phase 1
Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial
- NCT05773144 · 219 participants · NA
Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer
- NCT05907980 · 219 participants · Phase 1
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors